Trior (CEO Sungho Woo), a biotech startup developing antibody-drug conjugate (ADC) platform technology, announced on the 28th that it has secured a new investment of 2.5 billion won from CKD Venture Investment, a venture capital firm affiliated with a pharmaceutical company. This brings Trior's accumulated Series B investment to 25 billion won.
This investment is part of Trioer's ongoing Series B round, which was structured as a multi-closed round. Previous investors included IMM Investment, KB Investment, LSK Investment, Shinhan Capital (joint GPs: Jin & Investment Partners, Regent Partners, and Snickpick Investment), Kiwoom Investment, Woori Venture Partners, Hyundai Technology Investment, and Shinhan Venture Investment.
CKD Venture Investment's participation in this round was facilitated by the "2025 Seoul Biohub IR DAY: Seoul Bio Fund Management Company Meetup," hosted by the Seoul Biohub in June. Seoul Biohub, a specialized incubation center for bio and medical startups operated by the Seoul Metropolitan Government, offers comprehensive support programs, including training, mentoring, commercialization, and investment linkages in addition to providing space.
Trioer is developing a solution to improve the therapeutic index of antibody-drug conjugate treatments based on its proprietary platform technology, and is attracting attention as a next-generation technology that can complement the limitations of existing ADC technology.
Woo Sung-ho, CEO of Trio, said, “Seoul Bio Hub is a startup platform that provides value beyond just the space it provides, and this investment was possible through the hub’s networking and IR programs.” He added, “Based on the secured investment, we will further advance our technology development and strengthen our foundation for global commercialization.”
- See more related articles
You must be logged in to post a comment.